
European Economic Area
European Economic Area
Northern IrelandREACH
Key Points of the DecisionOn 9 April 2024, the Board of Appeal of the European Chemicals Agency issued a pivotal decision in the case of Dragon Chemical Europe GmbH versus the European Chemicals Agency. This case, identified as A-008-2022, centred on the chemical substance 5-amino-o-cresol, with the Agency's initial decision made on 24 May 2022, under Article 46 of the REACH Regulation.Parties InvolvedAppellant: Dragon Chemical Europe GmbH, GermanyRepresentatives for the Appellant: Ruxandra Cana, Eléonore Mullier, and Hannah Widemann from Steptoe LLP, BelgiumInterveners: The National Institute of Health, Italy; PETA Science Consortium International e.V., GermanyDecision Background
Published in April 2024. Dates, deadlines and stages may have changed since.
2 min readAI-drafted, expert reviewed

On 9 April 2024, the Board of Appeal of the European Chemicals Agency issued a pivotal decision in the case of Dragon Chemical Europe GmbH versus the European Chemicals Agency. This case, identified as A-008-2022, centred on the chemical substance 5-amino-o-cresol (CAS 2835-95-2), with the Agency's initial decision made on 24 May 2022, under Article 46 of the REACH Regulation.
Appellant: Dragon Chemical Europe GmbH, GermanyRepresentatives for the Appellant: Ruxandra Cana, Eléonore Mullier, and Hannah Widemann from Steptoe LLP, BelgiumInterveners: The National Institute of Health, Italy; PETA Science Consortium International e.V., Germany
The European Chemicals Agency's contested decision required Dragon Chemical Europe to provide additional in vivo testing data to assess the mutagenicity potential of 5-amino-o-cresol. The decision was challenged on several legal grounds, including errors in assessment, proportionality, protection of legitimate expectations, and a failure to adequately state reasons.
The Board of Appeal, comprising Chairman Antoine Buchet, Technically Qualified Member Nikolaos Georgiadis, and Legally Qualified Member and Rapporteur Marijke Schurmans, thoroughly examined the case. After detailed consideration of all arguments and evidence, including those presented at an oral hearing on 3 October 2023, the Board reached its conclusions.
Error in Risk Assessment: The Board identified errors in the Agency's risk assessment regarding the substance's potential for mutagenicity.Admissibility of Pleas: Some of the pleas by the PETA Science Consortium were deemed admissible as they were connected to the main subject matter of the dispute.Principle of Proportionality: The Board found that the Agency had breached the principle of proportionality by not adequately demonstrating that the requested tests were necessary and the least onerous measure.Legitimate Expectations and Duty to State Reasons: It was concluded that the Agency had not breached the appellant’s legitimate expectations or its duty to state reasons adequately.Animal Welfare Considerations: The decision emphasized adherence to the principle of using animals for testing only as a last resort, aligning with European Union regulations on animal welfare.
The annulment of the contested decision highlights the rigorous checks and balances in place within the European regulatory framework concerning chemical evaluations. This decision underscores the importance of adhering to scientific and legal standards in environmental and public health protection measures.
Official source
echa.europa.euTopics

Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanForesight follows changes like this one and shows where they reach your substances, products and markets.

European Economic Area

European Economic Area

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at